Literature DB >> 17362737

Calculation and comparison of the model for end-stage liver disease (MELD) score in patients accepted for liver transplantation in 1999 and 2004.

A Flodén1, M Castedal, S Friman, M Olausson, L Backman.   

Abstract

There has been a need to assess the "sickness degree" in patients with acute and chronic hepatic failure. The Model for End-Stage Liver Disease (MELD) score was developed as a tool for a more objective estimate of the "degree" of sickness in patients with chronic liver disease. In this study, the MELD score was retrospectively calculated and compared in adult patients accepted for orthotopic liver transplantation (OLT) in our institution in 1999 and 2004. We analyzed the gender, age, and MELD score associated with different indications for OLT during this period.

Entities:  

Mesh:

Year:  2007        PMID: 17362737     DOI: 10.1016/j.transproceed.2007.01.013

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


  3 in total

1.  Comparison of the Child-Turcotte-Pugh classification and the model for end-stage liver disease score as predictors of the severity of the systemic inflammatory response in patients undergoing living-donor liver transplantation.

Authors:  Sang-Hyun Hong; Jeong-Eun Kim; Mi-La Cho; Yu-Jung Heo; Jong-Ho Choi; Jung-Hyun Choi; Jaemin Lee
Journal:  J Korean Med Sci       Date:  2011-10-01       Impact factor: 2.153

2.  Preoperative predictors of blood component transfusion in living donor liver transplantation.

Authors:  R N Makroo; Rimpreet Singh Walia; Sanjeev Aneja; Aakanksha Bhatia; Mohit Chowdhry
Journal:  Asian J Transfus Sci       Date:  2013-07

3.  Polymethyl Methacrylate-Based Smart Microfluidic Point-of-Care Testing of Prothrombin Time and International Normalized Ratio through Optical Detection.

Authors:  Enas W Abdulhay; Ruba E Khnouf; Yahia M Karain; Taqwa K Al Omari; Nourshan M Ebeid; Tamara H Al Muhtaseb; N Arunkumar; M Thilagaraj; Gustavo Ramirez-Gonzalez
Journal:  Comput Math Methods Med       Date:  2022-02-18       Impact factor: 2.238

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.